secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2024-02-22T23:59:59+00:00
Accession:  0000950170-24-018764
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma FY2023 net loss $117.7M; LIFT-AD enrollment complete; data H2 2024
--------------------------------------------------------------------------------

- Net loss $117.7M ($3.09/sh) vs $95.6M ($2.53/sh) in FY2022; R&D spend rose to $93.8M.
- Cash and investments $147.4M as of Dec 31, 2023, down from $245.2M at end of 2022.
- Phase 2/3 LIFT-AD trial (fosgonimeton) enrollment completed (~315 pts); topline data expected H2 2024.
- First-in-human study of ATH-1105 for ALS on track to initiate in H1 2024.
- Adopted 2024 Inducement Plan reserving 750,000 shares; appointed COO/Chief Dev Officer and Chief People Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000095017024018764/0000950170-24-018764-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000095017024018764/atha-20240221.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-018764

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer